
Ref: 1) Review application dated 25.08.2017
2) NPPA notification under review S.O. 2401(E), dated 28.07.2017
3) Record Note of discussions held in the personal hearing held in the matter on 31.10.2017.

1. This is a petition under paragraph 31 of the Drugs (Prices Control) Order, 2013 (hereinafter called the DPCO) filed by M/s Aculife Healthcare Private Limited (hereinafter called the petitioner) against notification S.O. No.2401(E), dated 28.07.2017 issued by the National Pharmaceutical Pricing Authority (hereinafter called the NPPA) fixing the ceiling price of Ringer Lactate Injection.

2. The petitioner has contended as under:-

a. The Application is being filed seeking review and withdrawal of S.O. No. 2401(E) dated 28.07.2017, whereby NPPA has fixed and made it applicable to any of the packaging which includes USP type II Glass Bottles/LDPE FFS bottles/PP BFS bottles/PVC pouches/Euro Head.

b. Company explained how NPPA fixed ceiling price of Ringer Lactate Injection under DPCO 2013 & revised it in contravention to provisions of DPCO 2013:-

(1) Ceiling price of Ringer Lactate Injection I.P. was fixed vide S.O. no. 2863(E) dt. 20/09/2013 at Rs.0.10 per ml. As per S.O. the price first time fixed for any pack—either Glass or Poly (LDPE).

(2) NPPA revised Ceiling price of Ringer Lactate Injection I.P. vide S.O. no. 1156(E) dt. 28/04/2014 @ Rs.0.11 per ml. This price was also for any pack—Glass or Poly(LDPE).

(3) As per S.O. 1192(E) dt. 22/03/2016 NPPA amended para 11 by inserting 2 sub paras. As per sub para 11(3) of the DPCO 2013,NPPA has been authorized to fix separate ceiling rice in respect of various variants, of which one is ‘type of Packaging’.

(4) After amendment, NPPA fixed few meetings and few manufacturers demonstrated packs of ‘Euro-head’. NPPA fixed higher ceiling price for ‘Euro-head’
under para 11(3) of DPCO 2013 as per S.O. 2210(E) dt. 24/06/2016 - for 8 products and for 8 manufacturers. The said S.O. did not contain product ‘Ringer Lactate Injection I.P.

(5). As per S.O. 2209(E) dt. 24/06/2016, NPPA fixed ceiling price of ‘Glass’ & ‘non-Glass’. Incidentally, this S.O. also do not cover product ‘Ringer Lactate Injection I.P.

(6). Review Order 31015/9/2015-PI.I dt. 05/05/2016 was having 1 review application dt. 18/10/2013 filed against S.O. 2863(E) dt. 20/09/2013. The said review application was disposed off with a direction to examine in the light of S.O. 1192(E) dt. 22/03/2016. Thus NPPA was expected to review ceiling price under para 11(3) of DPCO 2013.

(7). S.O. dt. 28/07/2017 has only 4 packs of Ringer Lactate Injection I.P.—100ml/250ml/500ml/1000ml. All these packs were covered under 1 S.O. as well earlier. There is no mention of ‘Type of Packaging’ in the S.O. dt. 28/07/2017. Had NPPA fixed ceiling prices for Glass/Non-PVC/ non-glass special features, Company could have understood that NPPA had considered ‘type of packaging’ and fixed ceiling price in compliance of Review Order no. 31015/9/2015-PI.I. dt. 05/05/2016. But there appears unilateral revision in ceiling price in the guise of para 11(3) of DPCO 2013, which otherwise not available under para 16 of the DPCO 2013.

(8). As per NPPA’s O.M. No. 8(34)/2016/DP/NPPA/Div.II dated 16.06.2017, draft working were notified, with intention to revise ceiling price of Ringer Lactate. On perusal of working it has been noticed that NPPA has considered price under DPCO 1995. When ceiling price had been notified under DPCO 2013, vide S.O. 2863(E) dt. 20/09/2013, there is no logic to either compare ceiling price under DPCO 1995 or consider ceiling price of 2011; in June 2017 more so, in view of direction as per Office memorandum of DOP, GOI dt. 20/04/2017 under file reference 31026/31/2016-PI.I(pt.iv) which reads — “we directs NPPA not to review ceiling price before 5 years”. The intention to review ceiling price is contrary to directions of DOP, GOI as well as para 16 of the DPCO 2013.

(9). As per para 16 of the DPCO 2013, NPPA can revise price after 5 years from date of S.O. no. 2863(E){ dt. 20/09/2013} but not before 20/09/2018. Accordingly, Company found that NPPA has exercised powers not vested under DPCO 2013 under para 16 but arbitrary revised price on 28/07/2017.

(10). In view of the above, company prayed as under:-

(i) The notification S.O. No. 2401 dt. 28th July 2017, be withdrawn immediately;
(ii) Ceiling price for different type of packs be fixed separately for Glass Bottles/LDPE FFS bottles/PP BFS bottles/PVC pouches/Euro Head.

3. **Comments of NPPA:**

I. Ceiling price of **Ringer Lactate Injection** was notified as Rs. 41.17/500ml pack, Rs. 72.38/1000ml pack, Rs.18.95/100 ml and Rs. 32.31/250 ml vide S.O. 2401(E) dated 28.07.2017 as per Para 4, 6, 10, 11, 14, 16, 17, & 18 of DPCO, 2013.
The company has stated that correct methodology was not followed in arriving at the ceiling price of **Ringer Lactate Injection**. The points raised by the company are not relevant. Price fixation has been done strictly in accordance with the provisions of DPCO, 2013. Details are as follows:-

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Company’s Grievances</th>
<th>NPPA’s comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Company has stated that NPPA for the first time notified ceiling price Rs.01.10/ml for <strong>Ringer Lactate Injection</strong> vide S.O. 2863(E) dated 20.09.2013 and the same was revised to Rs. 0.11/ml by NPPA vide S.O. 1156(E) dated 28.04.2014. This price was applicable for any pack - Glass or Poly (LDPE).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>As per S.O. 1192 (E) dated 22.03.2016, NPPA amended Para 11 by 2 sub-Para’s. As per sub-Para 11(3) of DPCO, 2013, NPPA has been authorized to fix separate ceiling price in respect of various variants, of which, one is “Type of packaging”.</td>
<td></td>
</tr>
</tbody>
</table>
|        | After amendment supra, NPPA fixed few meetings and few manufacturers demonstrated packs of “Euro-Head”. NPPA was gracious to fix higher ceiling price for “Euro-Head” as per S.O. 2210(E) dated 24.06.2016- for 8 products and for 8 manufacturers. The said S.O. did not contain product “**Ringer-Lactate Injection**”.
|        | Vide S.O. 2209(E) dated 24.06.2016, NPPA fixed ceiling price of ‘Glass, Non-Glass’. Incidentally, this S.O. also does not cover product “**Ringer Lactate Injection**”.
|        | Review order 31015/09/2015-PI.I dated 05.05.2016 was having one review application dated 18.10.2013 filed against S.O. 2863 (E) dated 20.09.2013. The said review application was disposed of with a direction to examine in the light of S.O. 1192 (E) dated 22.03.2016. Thus, NPPA was expected to review ceiling |
|        | NPPA fixed ceiling price of **Ringer Lactate Injection** as Rs. 41.17/500ml pack and Rs. 72.38/1000ml, Rs.18.95/100ml and Rs.32.31/250 ml pack vide S.O. 2401(E) dated 28.07.2017 as per the directions given by DOP vide review order no. 31015/9/2015-PI.I dated 05.05.2016 against the review filed by M/s. **B. Braun**. DOP vide review order no. 31015/9/2015-PI.I dated 05.05.2016 passed an order along with other 8 representations to examine the case in light of S.O. 1192(E) dated 22.03.2015 under para 11(3) of DPCO 2013. |
|        | NPPA uploaded draft-working sheet of proposed ceiling price of this formulation on its website. The draft-working sheet placed on the website of NPPA on 16.06.2017 i.e. 40 days before price notification. M/s. **Aculife Healthcare Pvt. Ltd.** did not make any representation/request against the proposed retail price uploaded on NPPA website considering special feature pack for subject formulation. |
|        | Reference is invited to review order no. 31015/74/2012-PI.I and 31015/75/2012-PI.I dated 17.02.2014 wherein DOP rejected the review application of M/s **B. Braun Medical India Pvt. Ltd.** and M/s. **Baxter (India) Pvt. Ltd.** against S.O. 2863(E) dated 20.09.2013 requesting for a separate pricing for separate packaging material in respect of the price fixation of Ringer Lactate Injection. Similarly, DOP vide review order no. 31015/40/2014-PI.I dated 05.08.2014 rejected the review |
price under Para 11 (3) of DPCO, 2013.

S.O. 2401 (E) dated 28.07.2017 has only 4 packs of "Ringer Lactate Injection"-100 ml/250 ml/500ml/1000 ml. All these packs were covered under one S.O. as well earlier. There is no mention of type of packaging in S.O. dated 28.07.2017. Had NPPA fixed ceiling prices for Glass/Non-PVC/Non-Glass special feature, we could have understood that NPPA has considered type of packaging and fixed ceiling price in compliance of review order no. 31015/9/2015-PI.I dated 09.05.2016.

But, there appears unilateral revision in ceiling price in the guise of Para 11(3) of DPCO, 2013, which otherwise not available under Para 16 of DPCO, 2013.

On perusal of draft working sheet as per OM 8 (34)/2016/DP/NPPA/Div.II dated 16.06.2017. It has been noticed that NPPA has considered price under DPCO, 1995. When ceiling price has been notified under DPCO, 2013, Vide S.O.2863 (E) dated 20.09.2013, there is no logic to either compare ceiling price under DPCO, 1995 or consider ceiling price of 2011. Price exercise of NPPA for notification of S.O. 2401(E) dated 18.07.2013 is against the direction of DOP, GOI, dated 20.04.2017 under file reference 31026/31/2013-PI.I (Pt.IV) which reads, “we directs NPPA not to review ceiling price before 5 years”.

This is also as per the provision of Para 16 of DPCO, 2013. Company has requested:-


2). To fix separate ceiling price for different type of packs considering Glass Bottles/LDPE FFS Bottles/PP BFS Bottles/PVC pouches/Euro Head.

application of M/s. Fresenius Kabi India Pvt. Ltd. against S.O. no. 1156(E) dated 28.04.2014 requesting for separate pricing for separate packaging material in respect of the price fixation of Ringer Lactate Injection. On the issue whether the variants available in the market have different therapeutic efficacy, the case pertaining to M/s Baxter and M/s. B. Braun have already been referred to Standing Technical Committee. Ringer Lactate is appearing in DPCO, 1995 as well as under DPCO, 2013 (NLEM 2011 and 2015) which is a common drug. NPPA fixed the ceiling price for subject formulation in order to implement the Review order no. 31015/9/2015-PI.I dated 05.05.2016. Therefore, issues raised by company have no merit.

NPPA has implemented the Review order no. 31015/9/2015-PI.I dated 05.05.2016.
The products are not appearing in the Pharmatrac.

III. Company has not challenged S.O. No. 2401(E) dated 28.07.2017 in any Court.

4. During the personal hearing, the representative of the Company further submitted that in addition to draft working sheet uploaded on NPPA website on 16.6.2017, NPPA has issued circular dated 24.6.2017 asking all IV fluid manufacturers to provide details of MAT of March, 2017. Against aforesaid circular, company has submitted its objection vide its letter dated 22.7.2017.

4.2 In reply, NPPA representative stated that they have no further comments in addition to as stated above.

5. Examination:

The company has submitted that the ceiling price fixed by NPPA for Ringer Lactate Injection vide SO 2401(E), dated 28.07.2017 is made applicable to any of the packaging which includes USP type II Glass Bottles/LDPE FFS bottles/PP BFS bottles/PVC pouches/Euro Head. Company requested for separate pricing based on type of packaging.

5.2 It is observed that NPPA has fixed the ceiling price of subject formulation based on pack sizes, i.e. 100ml, 250ml, 500ml and 1000ml. However, type of packaging was not taken into account by NPPA while fixing the ceiling prices on the ground that there is no provision in DPCO to consider separate pricing on the basis of cost of packaging. NPPA invited the reference of Review Orders No.31015/74/2012-PI.I and 31015/75/2012-PI.I, dated 17.2.2014, in respect of M/s B.Braun Medical India Pvt. Ltd. and M/s Baxter (India) Pvt. Ltd. against SO 2863(E), dated 20.09.2013 and Review Order No.31015/40/2014-PI.I, dated 05.08.2014 in respect of M/s Fresenius Kabi India Pvt. Ltd. against SO No.1156(E), dated 28.4.2014 wherein DoP rejected the review applications of companies requesting separate pricing for separate packaging material in respect of price fixation of Ringer Lactate Injection.

5.3 It may be mentioned here that in DPCO, 2013, there was no provision of examination by Committee of Experts in the year 2014 when the review orders, referred to above by NPPA, were issued by DoP. However, vide SO 1192(E), dated 22.03.2016, para 11(3&4) were inserted in DPCO, 2013, wherein a provision was made to form a Committee of Experts, which reads as under:-

"11(3) Notwithstanding anything contained in sub-paragraph (1) and (2), in the case of injections or inhalation or any other medicine for which dosage form or strength or both are not specified in the Schedule-I of the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specified therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely, liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation."
11(4) The Government shall form a Committee of Experts, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the above parameters.”

5.4 It would be seen therefrom that the Committee of Experts is formed to consider and give its recommendation on notifying separate ceiling price or retail price for such formulations with specified therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be. In the instant case, before fixing the ceiling price of Ringer Lactate Injection, NPPA has not taken the opinion of Committee of Experts.

5.5 It is worth mentioning here that earlier various companies filed review applications in 2013, 2014 and 2015 for fixation of ceiling price of IV fluids based on type of packaging against NPPA’s notifications fixing ceiling price of IV fluids [Glucose 5%, Normal Saline Injection (Sodium Chloride 0.9%) and Ringer Lactate Injection] vide SOs No.2863(E), dated 20.9.2013; 3127(E), dated 10.12.2014 and 3131(E), dated 10.12.2014. The list of such companies is as under:-

i) M/s Fresenius Kabi India Pvt. Ltd. – petition dt.7.1.2015 against SO 3127(E), dt.10.12.2014 fixing ceiling price of Glucose and Sodium Chloride.


iii) M/s B.Braun Medical (India) Limited – petition, dt.18.10.2013 against SO 2863(E), dt.20.9.2013 fixing ceiling price of Ringer Lactate Injection.


v) M/s B.Braun Medical (India) Limited – petition, dt.7.1.2015 against SO 3127(E), dt.10.12.2014 fixing ceiling price of Glucose and Sodium Chloride.


vii) M/s Nirma Limited (Healthcare Division) – petition, dt.5.1.2015 against SO 3127(E), dt.10.12.2014 fixing ceiling price of Glucose and Sodium Chloride.


ix) M/s AXA Parenterals Ltd. – petition, dt.7.1.2015 against SO 3127(E), dt.10.12.2014 fixing ceiling price of Glucose and Sodium Chloride.

5.6 Keeping in view the similar nature of grievance of above pharma companies for fixation of separate ceiling price of IV fluids based on types of packaging, DoP, vide its Order No.31015/9/2015-PI.I, dated 5th May, 2016, directed NPPA to examine the review applications of above pharma companies under para 11(3&4) of DPCO, 2013.

5.7 On the direction of DoP, NPPA referred the matter to Committee of Experts, and based on the recommendation of the Committee, separate ceiling prices of two types of IV fluids, i.e Glucose and Sodium Chloride for Glass, PVC and Non-PVC packaging were fixed vide SO No.1993(E), dated 3.6.2016.
5.8 Later on, the following IV fluid manufacturing companies represented for fixation of separate ceiling prices based on different types of packaging as glass, non-glass and non-glass with special features:

i) M/s B.Braun Medical (I) Pvt. Ltd. manufacturing Ecoflac Plus bottle with Eurohead;

ii) M/s Amanta Healthcare Ltd. manufacturing Steriport bottle;

iii) M/s Aculife Healthcare Pvt. Ltd. manufacturing Aculife bottle with Eurohead;

iv) M/s Albert David Limited manufacturing Albert David bottle with Eurohead;

v) M/s Denis Chem Limited manufacturing Aquapulse with Eurohead;

vi) M/s Claris Life Sciences Limited manufacturing Claris bottle with Eurohead;

vii) M/s Fresenius Kabi India Pvt. Limited manufacturing Freeflex bags; and


5.9 Based on the representations from above company and feedback from various glass and non-glass manufacturers and on its own examination, NPPA modified the previous categorization of different types of packaging as glass, non-glass and non-glass with special features. Accordingly, NPPA re-fixed the ceiling price of aforesaid formulation for category of glass and non-glass vide SO 2209(E), dated 24.6.2016 and for non-glass with special features vide SO 2210(E), dated 24.6.2016. The above categorization based on types of packaging covered only Glucose and Sodium Chloride, but did not contain 'Ringer Lactate Injection', which is also in the category of IV Fluid.

5.10 Glucose, Sodium Chloride and Ringer Lactate are the various types of IV fluids having similarity in nature. NPPA has fixed the separate ceiling prices of only two types of IV fluids, i.e. Glucose and Sodium Chloride, based on different type of packagings. However, in case of Ringer Lactate, only type of fluid is changing and not the containers. Different methodology cannot be followed with the similar nature of IV fluids.

5.11 In view of the above, as was done in the case of other IV Fluids, NPPA may be directed to refer the matter to Committee of Experts for fixation of separate ceiling prices of Ringer Lactate Injections considering type of packaging, as per provision in para 11(3&4) of DPCO, 2013. On the basis of recommendations of the Expert Committee, separate prices may be fixed for subject formulation.

6. **Government Decision:**

“NPPA is hereby directed to refer the matter to Committee of Experts for examination of the claim of fixation of separate ceiling prices of Ringer Lactate Injections considering the types of packagings, as per para 11(3&4) of DPCO, 2013, after giving an opportunity to the petitioners to represent their case before the Committee of Experts. On the basis of recommendations of the Committee of Experts, appropriate decision may be taken on pricing of the subject formulation within a month by the NPPA.”
Issued on this date, the 21st day of March, 2018.

(M.K. Bhardwaj)
Deputy Secretary
For and on behalf of the President of India

To
1. M/s Aculife Healthcare Private Limited,
   Commerce House-V, Besides Vodafone House,
   Prahalad Nagar, Corporate Road,
   Ahmedabad-380 051.
2. The Member Secretary,
   National Pharmaceutical Pricing Authority,
   YMCA Cultural Centre Building, New Delhi-110001

Copy to:
1. PS to Hon'ble Minister (C&F), Shastri Bhawan, New Delhi for information.
2. PSO to Secretary (Pharma), Shastri Bhawan, New Delhi for information.
3. T.D., NIC for uploading the order on Department’s Website